Multiple myeloma (MM) is an incurable haematological malignancy, but patient survival outcomes have been lately improved by ...

The wind, a whisper across the unforgiving plains of Balochistan, carries tales not of ancient lore, but of a modern ...

In fact, malignancy is the third most common cause of death in renal transplant recipients. Immunosuppressive treatments used in renal transplant recipients can cause malignancy by supporting ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Learn the crucial differences between IBS and colon cancer symptoms, risk factors, and treatments to protect your digestive ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

Take a 30-day trial Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days Sign Up Sign Up ...

Of 50 deaths, 44% were attributed to infection, 25% to malignancy, and 20% to active vasculitis. Overall survival was 80.3%, with no significant difference between c-ANCA/PR3 (81%) and p-ANCA/MPO ...

Safety and efficacy of chimeric antigen receptor (CAR)–T cell therapy (BRG01) targeting the Epstein-Barr virus (EBV) envelope protein in EBV+ lymphoproliferative disease patients. Cumulative incidence ...

Molecular diversity in neuroendocrine tumors: A house divided.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet ...